These results suggest that changes in the expression levels of ACE are an early event during carcinogenesis and could be used as an efficient biomarker for the diagnosis of ovarian cancer compared to angiotensin II or Ca-125. The gene discussed is AGT; the disease is ovarian carcinoma.